ASX:SUD - Suda Pharmaceuticals Stock Price, Forecast & News

Suda Pharmaceuticals Ltd operates as a drug delivery company that focuses on oro-mucosal administration in Australia. Its product pipeline includes ZolpiMist, a US approved, oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia; ArTiMist, a sub-lingual spray for the treatment of p. falciparum severe paediatric malaria; SUD-001, an oral spray formulation that is used for the treatment of acute migraine in adults; and SUD-002, an oral spray formulation of ondansetron to treat nausea and vomiting induced by chemotherapy or radiotherapy, and other post-operative settings. Its product pipeline also comprises SUD-003, an oral spray formulation of sildenafil sprayed directly in the mouth over the tongue for the treatment of erectile dysfunction; SUD-004, an oral spray formulation of sildenafil to treat pulmonary arterial hypertension in adults; and SUD-005, an oral spray formulation of midazolam for the treatment of pre-procedure anxiety in imaging and dental procedures, and also in the treatment of epileptic seizures. In addition, it distributes medical devices, pharmaceuticals, vaccines, and consumables to hospitals, aged care facilities, pharmacies, mining companies, and other healthcare providers. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH for ZolpiMist oral spray. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd is based in Osborne Park, Australia.